Search for Biosample

Included Properties

Data Type
Project
Lab
Sample Type
4DN Cell Line Tier
Biosource
Organism
Modifications
Treatments
Status
Commendations
Warnings
3483 Results
Title
Organism
Biosource
Sample Type
Modifications
Treatments
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (10.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (10.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (8.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (8.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (6.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (6.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 8.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 8.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 6.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 6.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 120.0m), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 120.0m), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 120.0m), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (3.5h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (3.5h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (3.5h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (3.0h), 4-thiouridine treatment (100.0 μM, 15.0m)